Article Text

Download PDFPDF

610 The Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): An Interim Report
  1. Nancy Olsen1,
  2. David Karp2,
  3. Duanping Liao1,
  4. Judith James3,
  5. Cristina Arriens3,
  6. Diane Kamen4,
  7. Mariko Ishimori5 and
  8. Christopher Striebich6
  1. 1Penn State College of Medicine
  2. 2University of Texas Southwestern Medical Center
  3. 3Oklahoma Medical Research Foundation
  4. 4Medical University of South Carolina
  5. 5Cedars Sinai Medical Center
  6. 6University of Colorado Anschutz Medical Center


Background Laboratory and clinical features of systemic lupus erythematosus (SLE) may precede the onset of clinically apparent and classifiable disease. Autoantibodies and cytokines have been shown to be present in the blood years before a diagnosis of SLE can be made. Furthermore, nonspecific symptoms such as arthralgias and skin rashes may appear but not be recognized as related to autoimmunity. Patients who have signs, symptoms and laboratory abnormalities associated with SLE but who do not fulfill classification criteria for this condition have been designated as having incomplete lupus erythematosus (ILE). Patients with ILE are at risk for transition to SLE and offer a window into study of therapies that might prevent progressive disease. The SMILE study was designed to investigate whether hydroxychloroquine (HCQ) treatment prevents ILE patients from accumulating additional SLE criteria and developing progressive disease.

Methods SMILE is a multicenter, NIH-funded randomized, placebo-controlled, double blind study of hydroxychloroquine in patients with ILE. Eligible individuals are 15-49 years of age and must have an ANA by IFA of at least 1:80 along with 1 or 2 additional SLICC criteria for SLE. After confirming ophthalmologic safety, patients are randomized (1:1) to receive HCQ or placebo for 24 months. Visits at 3 month intervals assess clinical and laboratory features and record SLICC criteria. Any participant who is found to meet SLICC classification criteria for SLE is required to exit from the trial. Biosamples are collected at each visit for measurement of autoantibody and cytokine arrays; other samples are banked for later studies.

Results Enrollment started at the beginning of 2018 and ended on July 28, 2022. At that time 256 patients had been screened and 185 enrolled into the randomized phase, slightly less than the planned enrollment of 192. The randomized participants are more than 90% female, and the average age is 33 years. The study population is predominantly White, and only 15% are Black or more than one race. A small number (5/256) screen-failed due to ophthalmologic findings. Greater than 45% of enrollees have added SLICC criteria during followup, including approximately 15% who have exited the study after achieving 4 or more SLICC criteria and thus classifying as SLE. No drug-related SAEs have been reported and treatment has not been unblinded for any participant. The last enrollee is predicted to exit the trial in mid-2024.

Conclusions The ILE definition used in SMILE targets a population in which accumulation of additional SLE criteria and transition to classifiable disease is observable within a 2 year study period. The enrolled population has a lower percentage of Black patients than anticipated, and whether this is due to a lower prevalence of the ILE stage of disease in these patients is of interest for further investigation. SMILE is generating a valuable biobank of samples for future mechanistic studies.

Acknowledgements Supported by NIH/NIAMS U01AR071077. NCTC03030118

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: .

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.